

Dr Richard Bruce Warren

Current position:

1 February 2010 – current
NIHR Clinical Senior Lecturer in Dermatology
Dermatology Centre, University of Manchester
Honorary Consultant Dermatologist
Salford Royal NHS Foundation Trust

Clinically qualified and clinically active (3 clinics per week)

Previous employment:

Sept 2008 – Feb 2010	NIHR Clinical Lecturer Dermatology, The University of Manchester
Sept 2005 – July 2008	MRC Clinical Research Fellow, The Dermatology Centre, The University of Manchester.
Jan 2003 – August 2005	Dermatology SPR, Royal Liverpool University Hospital, Liverpool

Education and qualifications:

1998	BSc Pharmacology (1st class Honours) - Liverpool Medical School
1999	MChB (Hons), Liverpool Medical School
2002	MRCGP
2008	PhD, Manchester University

Recent Grant income:

- **NIHR Senior Clinical Lecturer** awarded 2010-2015. £250,000
- **NIHR Clinical Lecturer** awarded 2008-2010. £120,000
- Programme in clinical pharmacology – Pharmacogenomic signatures of treatment response in psoriasis. Principle supervisor **MRC NW England Clinical Research Training Fellowship**, 2010-2013
- Programme in clinical pharmacology - Investigation of immunogenicity in response to biological therapy for autoimmune disease. Co-supervisor **MRC NW England Clinical Research Training Fellowship** 2012-2015

- Genetic Susceptibility To Psoriasis and Psoriatic Arthritis and The Pharmacogenetics of its Biologic Therapeutic Treatment Programme. Principle Investigator **Abbott** 2010-2014. £128,994
- Towards an understanding of the critical role of psychosocial stress in psoriasis. Co-investigator. **Pfizer**, 2011-2013. £156,000
- A multi-Centre, prospective, cohort study to establish clinically relevant pharmacogenetic markers of systemic treatment outcomes in patients with severe psoriasis. Co-Investigator **Psoriasis Association** 2011 £69,000
- An exome scanning approach to the investigation of ANTI-TNF Induced Palmo-Plantar Psoriasis, Principle Investigator **British Skin Foundation** 2012 £10,000
- The potential of Pharmacogenetics to optimize methotrexate therapy for psoriasis **MRC Clinical Research Training Fellowship**. PhD student 2005-2008 £186,000
- Genetic variants in the IL1B region are key discriminators between early and late onset psoriasis. **Sir Jules Thorn PhD Scholarship**. £84,000
- An investigation into genetic factors which discriminate psoriasis from psoriatic arthritis. **Psoriasis association PhD Award**. £87,000

Supervision of research students:

5 PhD students, lead supervisor for 2 and co-supervisor for 3

Academic standing:

NIHR Clinical Senior Lecturer

Expert member-National Institute for Health and Clinical Excellence Guidelines for psoriasis

Chair -British Association of Dermatologists Methotrexate Guideline group

Member -British Association of Dermatologists Biologics Research Subcommittee

Member -British Association of Dermatologists Biologics Committee

Councillor -International Psoriasis Council

Member - Psoriasis International Network Scientific Committee

Editor - Dermatology and Therapy

**Selected recent relevant publications
(Total 71 PubMed, H Index 15):**

Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CEM. Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. *J Invest Dermatol.*2008; **128**: 1925-9.

Smith RL, **Warren RB**, Eyre S, Ho P, Ke X, Young HS, Griffiths CEM, Worthington J. Polymorphisms in the interleukin-12 β and interleukin-23R genes are associated with psoriasis of early onset in a UK cohort. *J Invest Dermatol* 2008; **128**: 1325-7.

Smith RL, **Warren RB**, Eyre S, Ke Z, Young HS, Allen M, Strachan D, McArdle W, Gittins MP, Barker JNWN, Griffiths CEM, Worthington J. Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. *Br J Dermatol* 2008; **158**: 962-8.

Capon F, Bijlmakers MJ, Wolf N, Quaranta M, Huffmeier U, Allen M, Timms K, Abkevich V, Gutin A, Smith R, **Warren RB**, Young HS, Worthington J, Burden AD, Griffiths CEM, Hayday A, Nestle FO, Reis A, Lanchbury J, Barker JNWN, Trembath RC. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. *Hum Mol Genet* 2008; **17**: 1938-45.

Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CE. Br J Dermatol. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. 2009 Feb; 160(2):438-41.

Ryan C, Menter A, **Warren RB**. Mol Diagn Ther. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. 2010 Apr 1;14(2):81-93.

Strange A, Capon F, Spencer CC, Knight J.....**Warren RB**, Weger W, Wolk K, Wood N, Worthington J, Young HS, Zeeuwen PL, Hayday A, Burden AD, Griffiths CE, Kere J, Reis A, McVean G, Evans DM, Brown MA, Barker JN, Peltonen L, Donnelly P, Trembath RC. Nat Genet. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, 2010 Nov; 42(11):985-90. Epub 2010 Oct 17.

Ali FR, Barton A, Smith RL, Bowes J, Flynn E, Mangino M, Bataille V, Foerster JP, Worthington J, Griffiths CE, **Warren RB**. An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene. Br J Dermatol. 2012 Oct 27. [Epub ahead of press]

Hébert HL, Ali FR, Bowes J, Griffiths CE, Barton A, **Warren RB**. Br J Dermatol Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. 2012 Mar; 166(3):474-82.

Burden AD, **Warren RB**, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, Ormerod AD, Griffiths CEM. BADBIR Study Group. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. *Br J Dermatol.* 2012; **166**: 545-54.

Hebert HL, Bowes J, Smith RL, Flynn E, Parslew R, Alshargi A, McHugh NJ, Barker JN, Griffiths CEM, Barton A, **Warren RB**. Identification of loci associated with late-onset

psoriasis using dense genotyping of immune-related regions. *Br J Dermatol*, 2014 Aug 13 [Epub ahead of print].

Hebert HL, Bowes J, Smith RL, McHugh NJ, Barker JN, Griffiths CEM, Barton A, **Warren RB**. Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. *J Invest Dermatol*. 2014 May; 134(5): 1459-62.

Samarasekera EJ, Neilson JM, **Warren RB**, Parnham J, Smith DH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. *J Invest Dermatol*. 2013 Oct, 133(10): 2340-6.

Mrowietz U, de Jong EM, Kragballe K, Langley R, Nast A, Puig L, Reich K, Schmitt J, **Warren RB**. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. *J Eur Acad Dermatol Venereol*, 2014, Apr; 28(4): 438-53

Coates LC, Aslam T, Al Balushi F, Burden AD, Burden-The E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). *Br J Dermatol*, 2013, 168,802-807.